The results of first-line treatment showed that the objective remission rate of FH-deficient RCC patients treated with E-B regimen was 50%, the median progression-free survival was 13.3 months, and the disease control rate was 90% (Zhou et al., 2021). Here, FH is linked to renal cell carcinoma.